MentalHealthDaily

GLP-1 Drugs for Parkinson’s: Lixisenatide Signal, Exenatide Miss

by GLOOM

Stylized illustration representing GLP-1 receptor agonists being investigated as potential disease-modifying treatments for Parkinson's disease.

Parkinson’s disease is the second most common neurodegenerative disorder, affecting around 10 million people worldwide. The mental-health burden is heavy: depression affects 40-50% of patients9, anxiety 30-40%, sleep disorders most patients eventually, and dementia about a third of long-duration cases. Standard treatment with levodopa controls motor symptoms but doesn’t slow the underlying neurodegeneration. The clinical …

Neuroprotective Agents: List of Drugs & Supplements

by GLOOM

Neuroprotective agents refer to substances that are capable of preserving brain function and structure. When the brain is exposed to high levels of oxidative stress, mitochondrial dysfunction, inflammation, various forms of neurotoxicity (e.g. excitotoxicity), and protein deficiencies – neurodegeneration can occur. To prevent or mitigate the effects of any neurodegeneration, strategic administration of a neuroprotective …